IGF-1 biological testing is a critical analytical service used to quantify the concentration and functional activity of Insulin-like Growth Factor 1, a key biomarker of growth hormone axis function. This guide provides a comprehensive overview of IGF-1 bioassay principles, acceptable sample types, validated detection methods, and applications in clinical diagnostics, anti-doping surveillance, and biopharmaceutical quality control.
Technical Overview
Insulin-like Growth Factor 1 (IGF-1), also known as somatomedin C, is a 70-amino acid single-chain polypeptide hormone with a molecular weight of approximately 7.6 kDa. Structurally homologous to proinsulin, IGF-1 functions as the principal mediator of growth hormone (GH) action and regulates cell proliferation, differentiation, apoptosis, and anabolic metabolism in virtually all tissues. Although GH secretion is markedly pulsatile, hepatic IGF-1 production integrates GH signaling over time and circulates at relatively stable concentrations, making IGF-1 the preferred clinical indicator of average GH axis activity.
In the systemic circulation, more than 99% of IGF-1 is complexed with six high-affinity insulin-like growth factor binding proteins (IGFBP-1 through IGFBP-6), predominantly IGFBP-3 and the acid-labile subunit. This binding extends the circulating half-life of IGF-1 to approximately 12 to 16 hours and presents a major analytical challenge: binding proteins must be dissociated or neutralized before accurate quantification is possible. IGF-1 biological testing therefore encompasses both immunometric mass quantification and functional bioassays that measure receptor-mediated proliferative activity.
Testing Samples
Serum
Serum is the standard specimen for IGF-1 measurement. Blood is collected by venipuncture, allowed to clot for 30 to 60 minutes, and centrifuged to separate the serum. Serum IGF-1 is stable for up to 5 days at 2 to 8 degrees Celsius, for several months at minus 20 degrees Celsius, and for long-term storage at minus 80 degrees Celsius. Repeated freeze-thaw cycles should be avoided.
Plasma
Plasma collected with EDTA or heparin anticoagulant is acceptable and is frequently used when multiple hormone analyses are planned from a single draw. Citrate plasma may be used but requires validation. Sample hemolysis and lipemia should be minimized to prevent analytical interference.
Specialized and Research Specimens
- Cerebrospinal fluid and amniotic fluid for neuroendocrine and developmental research
- Tissue homogenates and cell lysates for local autocrine and paracrine IGF-1 studies
- Cell culture supernatants for recombinant IGF-1 production monitoring and bioprocess development
- Formulated drug products and bulk drug substance for biopharmaceutical release testing
Testing Items
Typical IGF-1 biological testing panels include the following measurable endpoints, which may be ordered individually or in combination depending on the study objective:
- Total IGF-1 concentration, representing the entire IGFBP-bound and unbound hormone pool
- Free or unbound IGF-1, reflecting the biologically immediately available fraction
- IGF-1 biological activity or potency, expressed in International Units relative to the WHO International Standard
- IGFBP-3 concentration as a complementary marker of GH axis status
- Combined biomarker scores, such as the GH-2000 discriminant function using IGF-1 and P-III-NP for anti-doping purposes
Testing Methods
Sandwich Immunoassays
Enzyme-linked immunosorbent assay (ELISA), chemiluminescent immunoassay (CLIA), and immunoradiometric assay (IRMA) platforms dominate routine IGF-1 testing. Because circulating IGFBPs interfere with antibody binding, samples are pretreated with acid-ethanol extraction or specialized dissociation buffers to release IGF-1 from the binding protein ternary complex. Modern assays are calibrated against the WHO International Standard 02/254 to harmonize results across laboratories and exhibit typical measuring ranges of 10 to 2000 ng/mL with intra-assay coefficients of variation below 10%.
Liquid Chromatography Tandem Mass Spectrometry
LC-MS/MS has emerged as the reference method for total IGF-1 quantification. Following solid-phase extraction or immunoaffinity enrichment, the protein is digested with trypsin and signature peptides are quantified by multiple reaction monitoring using stable isotope-labeled internal standards. This approach eliminates antibody cross-reactivity with IGF-2, provides superior specificity and lot-to-lot consistency, and achieves limits of quantification below 5 ng/mL.
Cell-Based Biological Assays
Functional bioassays measure the proliferative potency of IGF-1 rather than its immunoreactive mass, which is essential for release testing of therapeutic products such as recombinant human IGF-1 (mecasermin). Validated formats include:
- Cell proliferation assays using IGF-1 receptor-expressing lines such as BALB/c 3T3 fibroblasts or MCF-7 cells, with growth stimulation quantified by BrdU incorporation, resazurin reduction, WST-1, or MTT colorimetry
- Kinase receptor activation assays (KIRA) using cells engineered to overexpress the human IGF-1 receptor, in which ligand-induced receptor autophosphorylation is captured and quantified by phosphotyrosine ELISA
- Dose-response curves analyzed by four-parameter logistic regression to derive EC50 values and relative potency against a calibrated reference standard
Applications
IGF-1 biological testing supports a wide spectrum of clinical, regulatory, and research activities:
- Diagnosis of growth hormone deficiency in children and adults, supported by age- and sex-adjusted reference intervals
- Diagnosis and post-surgical monitoring of acromegaly and gigantism, where elevated IGF-1 confirms GH excess
- Monitoring of recombinant GH replacement therapy and assessment of treatment adherence
- Anti-doping surveillance of growth hormone abuse using longitudinal biomarker profiling
- Potency and lot-release testing of recombinant IGF-1 biopharmaceuticals in accordance with pharmacopeial bioassay requirements
- Preclinical and academic research into cancer biology, sarcopenia, metabolic disease, wound healing, and aging
- Nutritional and anabolic status assessment in critical illness, chronic malnutrition, and hepatic dysfunction
FAQ
Question: Does IGF-1 testing require fasting or timed collection?
Unlike GH, IGF-1 does not exhibit dramatic pulsatility, so random sampling is generally acceptable. However, morning collection after an overnight fast is recommended because insulin and nutritional status can modestly influence circulating concentrations.
Question: Why are age and sex so important for interpretation?
IGF-1 concentrations rise through childhood, peak during pubertal growth at two to three times adult levels, and decline progressively with age. Laboratory results must always be interpreted against carefully partitioned age- and sex-specific reference intervals, ideally expressed as standard deviation scores.
Question: What is the difference between an immunoassay and a bioassay for IGF-1?
An immunoassay quantifies the immunoreactive mass of IGF-1 irrespective of function, whereas a cell-based bioassay measures the biological activity of the molecule through receptor binding and downstream proliferative signaling. Bioassays are indispensable when evaluating the potency of therapeutic IGF-1 preparations.
Question: What are the main sources of analytical interference?
Incomplete dissociation of IGFBPs, heterophilic antibodies, rheumatoid factor, severe hemolysis, and anti-reagent antibodies can all bias immunoassay results. LC-MS/MS confirmation is recommended when immunoassay results are inconsistent with the clinical picture.
Question: How stable are samples during transport?
Serum and plasma remain valid for approximately 5 days when shipped refrigerated at 2 to 8 degrees Celsius. For longer storage or international shipment, samples should be frozen at minus 70 degrees Celsius or below and transported on dry ice to avoid degradation and repeated freeze-thaw cycles.